Welcome to our dedicated page for GALECTIN THERAPEUTICS SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galectin Therapeutics Inc. filings document a clinical-stage biotechnology issuer developing galectin-targeted therapeutics, including belapectin for MASH cirrhosis and portal hypertension. Form 8-K reports furnish operating results, financial condition updates, business updates, Regulation FD materials, and clinical-program disclosures tied to NAVIGATE trial presentations and corporate presentations.
The company’s proxy and governance filings cover director elections, advisory votes on executive compensation, auditor ratification, board changes, officer compensation arrangements, and annual meeting results. Its SEC records also identify GALT common stock registered on The Nasdaq Stock Market and include risk-factor references related to forward-looking clinical development and financing needs.
Richard E. Uihlein reports beneficial ownership of 54,673,646.00 shares of Galectin Therapeutics Inc. common stock, representing approximately 49.30% of the outstanding class. He has sole voting and sole dispositive power over these shares, which are held for investment purposes rather than to change or influence control.
The stake consists of 44,736,553 shares of common stock and 9,937,093 shares issuable upon conversion of warrants, options and other convertible securities. On July 31, 2026, he converted debt of approximately $105.8, consisting of $91.0 million of principal and approximately $14.8 million of accrued interest, into 34,376,167 shares of common stock. His investment is described as funded with personal funds.
Galectin Therapeutics director and over-10% holder Richard E. Uihlein, via the Richard E. Uihlein Stock Trust, exercised Line of Credit Convertible Notes into 31,825,235 and 2,550,932 common shares at $3.00 and $4.05 per share. The notes totaled $91,000,000 and $10,000,000 of principal plus accrued interest. A holding entry reports 27,710 shares held by the Ed Uihlein Family Foundation, where Uihlein shares voting power but has no pecuniary interest.
Galectin Therapeutics Inc. converted approximately $105.8 million of debt owed to its chairman and largest stockholder, Richard E. Uihlein, into equity effective July 31, 2026. The conversion eliminated $91.0 million of principal and about $14.8 million of accrued interest arising from five line-of-credit facilities.
In exchange, the company issued 34,376,167 shares of common stock at a blended average conversion price of about $3.07 per share, using the Section 3(a)(9) exemption from registration. After the transaction, 100,849,644 common shares and 197,500 Series A Voting Preferred shares were outstanding, and Mr. Uihlein beneficially holds roughly 44.3% of voting power, or 49.3% including warrants. A separate $10 million supplemental credit facility from December 2025 remains undrawn and available, and the company is obligated to register the resale of the new shares within 180 days of conversion.
Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised stock options to acquire 16,250 common shares at $3.04 per share and sold 16,250 shares at a weighted average price of $5.1252 on July 14, 2026, under a Rule 10b5-1 trading plan. Following the derivative transaction, he held 48,750 stock options.
Galectin Therapeutics director Harold H. Shlevin reported option exercises paired with share sales in Galectin Therapeutics Inc. common stock. On June 26 and June 29, 2026, he exercised stock options to acquire a total of 30,000 shares at an exercise price of $1.23 per share and sold 30,000 shares in open-market transactions.
Sales on June 26 covered 7,732 shares at $5.00 per share, while June 29 sales covered 22,268 shares at a weighted average price of $5.04, with individual trades ranging from $5.00 to $5.12. The filing notes these transactions were executed under a Rule 10b5-1 trading plan adopted on August 29, 2025. After these trades, Shlevin directly holds 6,500 shares of Galectin common stock, and the exercised options had fully vested on December 31, 2025.
GALECTIN THERAPEUTICS INC Chief Medical Officer Jamil Khurram exercised and sold stock options in a paired set of transactions. On June 26 and 29, 2026, he exercised options covering 52,037 shares of common stock at exercise prices of $2.20 and $2.50 per share, then sold the same number of shares in open‑market sales around $5.00–$5.04 per share. The filing shows these trades were executed under a Rule 10b5-1 trading plan adopted on February 2, 2026, and reports that Khurram held no remaining common shares or related options from these grants immediately after the transactions.
GALT Group, Inc. notice of proposed sale of Common Stock by affiliate Harold Shlevin. The filing lists a stock option exercise with CASH UPON EXERCISE and records a sale on 06/26/2026 of 7,732 shares. The filing also shows 38,680 in the same row.
GALT reports a Rule 144 notice covering proposed sales of Common Stock. The filing lists multiple stock option exercises and recent disposals by an individual, including sales of 568 shares on 05/26/2026 and 7,557 shares on 06/23/2026. The document names Khurram Jamil as the seller and shows prior stock option exercises totaling 16,250, 2,037, and 50,000 shares on the dates provided.
GALECTIN THERAPEUTICS INC Chief Medical Officer Jamil Khurram exercised stock options and sold the resulting shares in a planned transaction. He exercised options to acquire 7,557 shares of common stock at $1.23 per share, then sold 7,557 shares at a weighted average price of $3.14 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026, indicating it was scheduled in advance. Following these transactions, he reported no directly held common shares and 32,500 stock options outstanding, with remaining options vesting in tranches of 16,250 on specified future dates.